How the pregabalin case has set back drug repurposing The 2018 Supreme Court verdict on Pfizer’s second patent for Lyrica has drawn attention to the limitations of the current framework for extending the usefulness of existing treatments.…
Pharmacy negotiators urge DHSC to allow pharmacies to trade stock without wholesale licence after Brexit Pharmacists should be allowed to exchange stocks of medicines to mitigate local medicines shortages after Brexit, pharmacy leaders have said.…
A quick guide to medical cannabis With medical cannabis now legal in 44 countries around the world, and the UK likely to follow suit, here is what pharmacists need to know.…
Medical cannabis: what will pharmacy’s role be? How the UK has realised the benefits of medical cannabis and the involvement pharmacists could have in its supply.…
EMA endorses strengthened regulatory measures for valproate The European Medicines Agency’s Coordination Group for Mutual Recognition and Decentralised Procedures — Human has endorsed strengthened measures to avoid valproate exposure during pregnancy.…
Cities compete to host EMA The European Medicines Agency (EMA) has assessed the bids of 19 cities that have applied to host its headquarters following the UK’s exit from the European Union in 2019. The final relocation decision will be made by the European Council on 20 November 2017.…
Any form of Brexit will hit UK healthcare, researchers warn Leaving the EU could profoundly affect medicines licensing and leave the NHS struggling to keep staff, a health policy review published in The Lancet has said.…
Three decades of Viagra Sildenafil (Viagra) — the first oral drug for erectile dysfunction to hit the market in 1998 — has been prescribed for more than 64 million men worldwide, and may soon be reclassified as a pharmacy medicine in the UK.…
Drug regulation in the UK: risks and opportunities post-Brexit While the implications of Brexit on drug regulation in the UK are largely unknown, the government needs to consider its options quickly to avoid delaying public access to important medicine.…
FDA speeds up approval for rare cancer drug Regulators in the United States have approved immunotherapy drug avelumab (Bavencio; Pfizer and Merck KGaA) for the treatment of a rare aggressive skin cancer under an accelerated evaluation process.…
